Life sciences leaders Ramon Felciano and Rickard El Tarzi join board as company scales commercialization of its molecular cell architecture platform

生命科学领域专家拉蒙·费尔西亚诺和里卡德·埃尔塔尔齐加入董事会，公司正加速推进其分子细胞架构平台的商业化进程

STOCKHOLM

斯德哥尔摩

,

，

Aug. 20, 2026

2026年8月20日

/PRNewswire/ --

/美通社/ --

Pixelgen Technologies

像素基因技术公司

, developer of the first high-throughput platform for mapping molecular cell architecture, today announced it has closed an oversubscribed $15.5 million (approximately SEK 150 million) Series B financing to accelerate global commercialization of its

，作为首个用于绘制分子细胞架构的高通量平台的开发商，今日宣布已完成一轮超额认购的1,550万美元（约合1.5亿瑞典克朗）B轮融资，以加速其全球商业化进程

Proxiome Kit

Proxiome 试剂盒

and expand the company's presence in key markets. The financing round was led by new investor Flat Capital, with continued participation from existing investors Industrifonden and Navigare Ventures.

并扩大公司在关键市场的布局。本轮融资由新投资方 Flat Capital 领投，现有投资方 Industrifonden 和 Navigare Ventures 继续跟投。

'This financing gives us the resources to expand globally as demand grows for our Proxiome Kit and our data analysis and visualization software,' said Pixelgen CEO and co-Founder Simon Fredriksson, PhD. 'We're proud to have Flat Capital join us and to have the continued confidence of Navigare and Industrifonden.

“这笔融资为我们提供了在全球范围内扩展的资源，以满足市场对Proxiome Kit以及我们的数据分析和可视化软件不断增长的需求。”Pixelgen首席执行官兼联合创始人Simon Fredriksson博士表示。“我们很荣幸Flat Capital加入我们，并继续获得Navigare和Industrifonden的信任。”

Their support will help accelerate our commercial reach, grow our team and product portfolio, and bring molecular cell architecture to more researchers and new applications.'.

他们的支持将有助于加速我们的商业化进程，扩大我们的团队和产品组合，并将分子细胞架构带给更多的研究人员和新的应用领域。

Pixelgen's Proxiome Kit is the first platform to enable high-throughput mapping of molecular cell architecture at nanoscale resolution, providing researchers with a new way to study cell function and disease mechanisms. While conventional proteomic approaches primarily measure protein abundance, the Proxiome Kit reveals how proteins are organized, clustered and localized on the surface of individual cells.

Pixelgen的Proxiome Kit是首个能够在纳米级分辨率下实现分子细胞结构高通量映射的平台，为研究人员提供了一种研究细胞功能和疾病机制的新方法。传统的蛋白质组学方法主要测量蛋白质的丰度，而Proxiome Kit则揭示了蛋白质在单个细胞表面的组织、聚集和定位方式。

Powered by the Proximity Network Assay, the Proxiome Kit enables researchers to investigate architectural features of cell state, disease and treatment response that are not captured by abundance measurements alone..

Proxiome试剂盒依托邻近网络检测技术，使研究人员能够探究仅靠丰度测量无法捕捉的细胞状态、疾病及治疗反应的结构特征。

'Pixelgen's technology gives researchers the ability to study disease mechanisms and identify novel biomarkers in an entirely new way. We believe this could open new avenues for research in cancer, immunology and autoimmune disease, while broadening our understanding of basic biology,' said Rickard El Tarzi, CEO of Flat Capital.

“Pixelgen 的技术使研究人员能够以全新的方式研究疾病机制并识别新型生物标志物。我们相信，这将为癌症、免疫学和自身免疫性疾病的研究开辟新途径，同时拓宽我们对基础生物学的理解。”Flat Capital 首席执行官 Rickard El Tarzi 表示。

'Pixelgen's leadership team has successfully commercialized multiple life sciences products globally, and we look forward to supporting the company through its next phase of growth.'.

“Pixelgen的领导团队已成功在全球范围内实现多款生命科学产品的商业化，我们期待在公司下一阶段的增长中为其提供支持。”

Alongside the financing, Pixelgen is adding Flat Capital CEO Rickard El Tarzi and life sciences industry veteran Ramon Felciano, Ph.D, to its board of directors.

伴随着此次融资，Pixelgen 公司任命 Flat Capital 首席执行官 Rickard El Tarzi 和生命科学行业资深专家 Ramon Felciano 博士加入其董事会。

El Tarzi brings extensive experience in investments, strategic development and board leadership from his time in private equity and industry. He joins the board in his capacity as CEO of Flat Capital. Previous experience includes serving as Chief Strategy & Product Officer at Olink Proteomics, now part of Thermo Fisher Scientifc, where he helped shape the company's strategic direction through its initial public offering and eventual sale..

塔尔齐先生在私募股权和实业领域积累了丰富的投资、战略发展和董事会领导经验。他以Flat Capital首席执行官的身份加入董事会。他此前的经历包括在Olink Proteomics（现为赛默飞世尔科技的一部分）担任首席战略与产品官，期间他帮助塑造了公司的战略方向，推动了公司首次公开募股及最终的出售。

Ramon Felciano, Ph.D., is a life sciences technology entrepreneur working at the intersection of data, technology, and life sciences. He founded Ingenuity Systems, a pioneer in AI-driven genome interpretation and precision medicine, acquired by QIAGEN in 2013 for $105 million. At QIAGEN he served as chief technology officer and vice president of data strategy, founding QIAGEN Digital Insights, the company's industry-leading molecular data and AI software business unit.

拉蒙·费尔西亚诺（Ramon Felciano）博士是一位生命科学科技企业家，致力于数据、技术与生命科学的交叉领域。他创立了Ingenuity Systems公司，该公司是人工智能驱动基因组解读和精准医疗领域的先驱，于2013年被QIAGEN以1.05亿美元收购。在QIAGEN期间，他担任首席技术官兼数据战略副总裁，并创立了QIAGEN Digital Insights，这是该公司行业领先的分子数据与人工智能软件业务部门。

On the board, Felciano will work with Pixelgen's leadership to build digital capabilities (software and data) that help translate the company's technical differentiation - the molecular cell architecture platform - into company-level competitive advantage..

在董事会层面，Felciano 将与 Pixelgen 的领导层合作，构建数字化能力（软件和数据分析），以将公司的技术差异化优势——即分子细胞架构平台——转化为公司层面的竞争优势。

'Rickard and Ramon bring highly complementary experience to Pixelgen at an important stage in our growth,' Fredriksson said. 'Rickard understands what it takes to scale and commercialize life sciences research platforms globally, while Ramon has built AI and data businesses with products that have been adopted by biotech R&D, a key sector for us moving forward.' .

“在我们增长的重要阶段，Rickard 和 Ramon 为 Pixelgen 带来了高度互补的经验，”Fredriksson 表示。“Rickard 深知在全球范围内扩展和商业化生命科学研究平台所需的关键要素，而 Ramon 则打造了 AI 和数据业务，其产品已被生物技术研发领域广泛采用，这对我们未来的发展至关重要。”

About Pixelgen Technologies

关于 Pixelgen Technologies

Pixelgen Technologies has commercialized the first high-throughput platform for mapping molecular cell architecture at nanoscale resolution, enabling researchers to analyze how proteins are organized, clustered and localized on the surface of single cells. Founded in 2020 by a team of experienced innovators and entrepreneurs and headquartered in Stockholm, the company helps researchers move beyond abundance measurements to capture the architectural features of cell state, disease and treatment response across immunology, hematology, oncology and cell therapy..

Pixelgen Technologies 已将首个能够在纳米级分辨率下绘制分子细胞架构的高通量平台商业化，使研究人员能够分析蛋白质在单细胞表面的组织、聚集和定位情况。该公司由一支经验丰富的创新者和企业家团队于 2020 年创立，总部设在斯德哥尔摩，帮助研究人员超越单纯的丰度测量，捕捉免疫学、血液学、肿瘤学和细胞治疗领域中细胞状态、疾病和治疗反应的架构特征。

Contacts

联系人

Corporate:

企业：

Annika Branting

安妮卡·布兰廷

[email protected]

[email protected]

+46 762-69 68 46

+46 762-69 68 46

Media:

媒体：

Susan Thomas

苏珊·托马斯

[email protected]

[email protected]

+1 (619) 540-9195

+1 (619) 540-9195

SOURCE Pixelgen Technologies

来源：Pixelgen Technologies

21

二十一

%

百分之

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示